Cargando…
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
BACKGROUND/AIMS: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). METHODS: In this study, 18 patients with previously diagnosed R/M HNSCC wer...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718762/ https://www.ncbi.nlm.nih.gov/pubmed/29914230 http://dx.doi.org/10.3904/kjim.2017.234 |
_version_ | 1783447791230517248 |
---|---|
author | Kim, Moon Jin Kim, Sung Min Jung, Hyun Ae Hong, Jung Yong Chang, Won Jin Choi, Moon Ki Kim, Hye Sook Sun, Jong-Mu Park, Keunchil Ahn, Myung-Ju |
author_facet | Kim, Moon Jin Kim, Sung Min Jung, Hyun Ae Hong, Jung Yong Chang, Won Jin Choi, Moon Ki Kim, Hye Sook Sun, Jong-Mu Park, Keunchil Ahn, Myung-Ju |
author_sort | Kim, Moon Jin |
collection | PubMed |
description | BACKGROUND/AIMS: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). METHODS: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m(2) (day 1 and 8) and cisplatin 70 mg/m(2) (day 1) as first-line chemotherapy, repeated every 3 weeks. RESULTS: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality. CONCLUSIONS: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment. |
format | Online Article Text |
id | pubmed-6718762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-67187622019-09-06 Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Kim, Moon Jin Kim, Sung Min Jung, Hyun Ae Hong, Jung Yong Chang, Won Jin Choi, Moon Ki Kim, Hye Sook Sun, Jong-Mu Park, Keunchil Ahn, Myung-Ju Korean J Intern Med Original Article BACKGROUND/AIMS: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). METHODS: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m(2) (day 1 and 8) and cisplatin 70 mg/m(2) (day 1) as first-line chemotherapy, repeated every 3 weeks. RESULTS: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality. CONCLUSIONS: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment. The Korean Association of Internal Medicine 2019-09 2018-06-20 /pmc/articles/PMC6718762/ /pubmed/29914230 http://dx.doi.org/10.3904/kjim.2017.234 Text en Copyright © 2019 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Moon Jin Kim, Sung Min Jung, Hyun Ae Hong, Jung Yong Chang, Won Jin Choi, Moon Ki Kim, Hye Sook Sun, Jong-Mu Park, Keunchil Ahn, Myung-Ju Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
title | Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
title_full | Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
title_fullStr | Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
title_full_unstemmed | Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
title_short | Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
title_sort | efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718762/ https://www.ncbi.nlm.nih.gov/pubmed/29914230 http://dx.doi.org/10.3904/kjim.2017.234 |
work_keys_str_mv | AT kimmoonjin efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT kimsungmin efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT junghyunae efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT hongjungyong efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT changwonjin efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT choimoonki efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT kimhyesook efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT sunjongmu efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT parkkeunchil efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT ahnmyungju efficacyandsafetyofcisplatinandweeklydocetaxelinpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck |